Current Breast Cancer Reports

, Volume 4, Issue 1, pp 48–55 | Cite as

Biology and Novel Targets in Metaplastic Breast Cancer

Systemic Therapy (J O’Shaughnessy, Section Editor)
  • 96 Downloads

Abstract

Metaplastic breast cancer represents a spectrum of histologic subtypes with the common feature of divergent morphologic differentiation. Most of these subtypes are associated with chemotherapy resistance and an increased likelihood of developing distant metastatic disease, which has been associated with a poor prognosis. However, recent molecular characterization has indicated that some metaplastic cancers may respond to targeted therapy regimens currently undergoing evaluation in early phase clinical trials. In this review, the pathologic characteristics and epidemiology of metaplastic breast cancer are discussed along with novel therapeutic agents that may augment standard chemotherapy for this intriguing type of breast cancer.

Keywords

Breast cancer Metaplastic Stem cell Triple-negative 

Notes

Disclosure

No conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol. 1989;20:732–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol. 1989;20:628–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer. 1989;64:1490–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer. 1990;65:272–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol. 1990;21:1142–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Gobbi H, Simpson JF, Borowsky A, et al. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer. 1999;85:2170–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Sneige N, Yaziji H, Mandavilli SR, et al. Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. Am J Surg Pathol. 2001;25:1009–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Van Hoeven KH, Drudis T, Cranor ML, et al. Low-grade adenosquamous carcinoma of the breast. A clinocopathologic study of 32 cases with ultrastructural analysis. Am J Surg Pathol. 1993;17:248–58.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosen PP, Ernsberger D. Low-grade adenosquamous carcinoma. A variant of metaplastic mammary carcinoma. Am J Surg Pathol. 1987;11:351–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Fisher ER, Palekar AS, Gregorio RM, Paulson JD. Mucoepidermoid and squamous cell carcinomas of breast with reference to squamous metaplasia and giant cell tumors. Am J Surg Pathol. 1983;7:15–27.PubMedCrossRefGoogle Scholar
  11. 11.
    Cardoso F, Leal C, Meira A, et al. Squamous cell carcinoma of the breast. Breast. 2000;9:315–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Toikkanen S. Primary squamous cell carcinoma of the breast. Cancer. 1981;48:1629–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Eggers JW, Chesney TM. Squamous cell carcinoma of the breast: a clinicopathologic analysis of eight cases and review of the literature. Hum Pathol. 1984;15:526–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Hennessy BT, Krishnamurthy S, Giordano S, et al. Squamous cell carcinoma of the breast. J Clin Oncol. 2005;23:7827–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Downs-Kelly E, Nayeemuddin KM, Albarracin C, et al. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 2009;33:534–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Davis WG, Hennessy B, Babiera G, et al. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 2005;29:1456–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Kaufman MW, Marti JR, Gallager HS, Hoehn JL. Carcinoma of the breast with pseudosarcomatous metaplasia. Cancer. 1984;53:1908–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Carter MR, Hornick JL, Lester S, Fletcher CD. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006;30:300–9.PubMedGoogle Scholar
  19. 19.
    Nguyen CV, Falcon-Escobedo R, Hunt KK, et al. Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival. Am J Surg Pathol. 2010;34;486–493.Google Scholar
  20. 20.
    • Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14:166–73. This is the largest study of the characteristics of metaplastic breast cancer.PubMedCrossRefGoogle Scholar
  21. 21.
    Rayson D, Adjei AA, Suman VJ, et al. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10:413–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg. 2006;191:657–64.PubMedCrossRefGoogle Scholar
  23. 23.
    Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17:605–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Lester TR, Hunt KK, Nayeemuddin KM, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat.Google Scholar
  25. 25.
    Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101:349–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Okada N, Hasebe T, Iwasaki M, et al. Metaplastic carcinoma of the breast. Hum Pathol.Google Scholar
  27. 27.
    Yamaguchi R, Horii R, Maeda I, et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol. 2010;41:679–685.Google Scholar
  28. 28.
    Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 120;627–637.Google Scholar
  29. 29.
    Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res. 2005;7:R1028–1035.PubMedCrossRefGoogle Scholar
  30. 30.
    Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209:445–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol. 2005;58:700–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Bossuyt V, Fadare O, Martel M, et al. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol. 2005;13:319–27.PubMedCrossRefGoogle Scholar
  34. 34.
    Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7:944–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007;13:90–101.PubMedCrossRefGoogle Scholar
  36. 36.
    Sitterding SM, Wiseman WR, Schiller CL, et al. AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol. 2008;12:33–40.PubMedCrossRefGoogle Scholar
  37. 37.
    Leibl S, Gogg-Kammerer M, Sommersacher A, et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol. 2005;29:347–53.PubMedCrossRefGoogle Scholar
  38. 38.
    Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol. 2003;11:1–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117:273–80.PubMedCrossRefGoogle Scholar
  40. 40.
    Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76.PubMedCrossRefGoogle Scholar
  41. 41.
    • Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–24. This article describes the high rate of PIK3CA mutations and molecular characteristics of subtypes of metaplastic breast cancer, including the high correlation with a cancer stem cell-derived molecular signature.PubMedCrossRefGoogle Scholar
  42. 42.
    Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.Google Scholar
  43. 43.
    Wada H, Enomoto T, Tsujimoto M, et al. Carcinosarcoma of the breast: molecular-biological study for analysis of histogenesis. Hum Pathol. 1998;29:1324–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Zhuang Z, Lininger RA, Man YG, et al. Identical clonality of both components of mammary carcinosarcoma with differential loss of heterozygosity. Mod Pathol. 1997;10:354–62.PubMedGoogle Scholar
  45. 45.
    Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol. 2010;220:562–73.PubMedCrossRefGoogle Scholar
  46. 46.
    Reis-Filho JS, Schmitt FC. p63 expression in sarcomatoid/metaplastic carcinomas of the breast. Histopathology. 2003;42:94–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Sproul D, Nestor C, Culley J, et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A. 2011;108:4364–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26:7859–71.PubMedCrossRefGoogle Scholar
  49. 49.
    Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 2004;3:1058–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Valsesia-Wittmann S, Magdeleine M, Dupasquier S, et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 2004;6:625–30.PubMedCrossRefGoogle Scholar
  51. 51.
    • Taube JH, Herschkowitz JI, Komurov K, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010;107:15449–54. This article details the features of metaplastic breast cancer that relate to epithelial-to-mesenchymal transition.PubMedCrossRefGoogle Scholar
  52. 52.
    Hayes MJ, Thomas D, Emmons A, et al. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008;14:4038–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Lacroix-Triki M, Geyer FC, Lambros MB, et al. beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol. 2010;23:1438–48.PubMedCrossRefGoogle Scholar
  54. 54.
    Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009;14:29–43.PubMedCrossRefGoogle Scholar
  55. 55.
    Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med. 2007;11:981–1011.PubMedCrossRefGoogle Scholar
  56. 56.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 2009;14:55–66.PubMedCrossRefGoogle Scholar
  58. 58.
    Debeb BG, Xu W, Woodward WA. Radiation resistance of breast cancer stem cells: understanding the clinical framework. J Mammary Gland Biol Neoplasia. 2009;14:11–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer chemoresistance: Emerging importance of cancer stem cells. Surg Oncol. 2009.Google Scholar
  60. 60.
    O’Brien CS, Howell SJ, Farnie G, Clarke RB. Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia. 2009;14:45–54.PubMedCrossRefGoogle Scholar
  61. 61.
    Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217–26.PubMedCrossRefGoogle Scholar
  63. 63.
    Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.PubMedCrossRefGoogle Scholar
  64. 64.
    Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106:13820–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A. 2007;104:16158–63.PubMedCrossRefGoogle Scholar
  66. 66.
    Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.PubMedCrossRefGoogle Scholar
  67. 67.
    Moulder S, Moroney J, Helgason T, et al. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011;29:e572–575.Google Scholar
  68. 68.
    Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8:99–110.PubMedCrossRefGoogle Scholar
  69. 69.
    Jain RK, Finn AV, Kolodgie FD, et al. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med. 2007;4:491–502.PubMedCrossRefGoogle Scholar
  70. 70.
    Bellino R, Arisio R, D’Addato F, et al. Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res. 2003;23:669–73.PubMedGoogle Scholar
  71. 71.
    Kochhar R, Howard EM, Umbreit JN, Lau SK. Metaplastic breast carcinoma with squamous differentiation: molecular and clinical analysis of six cases. Breast J. 2005;11:367–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Nusse R. Wnt signaling in disease and in development. Cell Res. 2005;15:28–32.PubMedCrossRefGoogle Scholar
  73. 73.
    Cheung YC, Lee KF, Ng SH, et al. Sonographic features with histologic correlation in two cases of palpable breast cancer after breast augmentation by liquid silicone injection. J Clin Ultrasound. 2002;30:548–51.PubMedCrossRefGoogle Scholar
  74. 74.
    Kloos I, Delaloge S, Pautier P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer. 2002;12:496–500.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Breast Medical Oncology, Unit 1354University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Phase I ProgramUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  3. 3.HoustonUSA

Personalised recommendations